Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Pharmacology

Background:

• Hypertension management is crucial for cardiovascular health.
• Thiazide diuretics, like hydrochlorothiazide, are common antihypertensive agents.
• Serum uric acid levels can be affected by antihypertensive therapies.

Purpose of the Study:

• To investigate the relationship between achieved blood pressure (BP) levels and serum uric acid changes.
• To assess the incidence of hyperuricemia in relation to BP control after 12 weeks of irbesartan/hydrochlorothiazide treatment.

Main Methods:

• A study involving 449 patients who completed 12 weeks of antihypertensive therapy.
• Analysis of covariance and logistic regression were used to analyze serum uric acid changes and hyperuricemia incidence.
• Patients were categorized based on achieved systolic and diastolic blood pressure (SBP/DBP) levels.

Main Results:

• Serum uric acid increases were smaller in patients with achieved SBP/DBP of 130-139/<90 mm Hg compared to other BP ranges.
• The risk of developing hyperuricemia was significantly lower (OR, 0.45) in the 130-139/<90 mm Hg BP group.
• These associations remained significant after adjusting for baseline serum uric acid levels.

Conclusions:

• Achieved blood pressure levels significantly influence thiazide-induced serum uric acid changes and hyperuricemia incidence.
• A target blood pressure of 130-139/<90 mm Hg is associated with more favorable effects on serum uric acid metabolism.
• This suggests that optimizing BP control can mitigate adverse effects of hydrochlorothiazide on uric acid levels.